EMA/138317/2016

European Medicines Agency decision

P/0061/2016

of 18 March 2016

on the acceptance of a modification of an agreed paediatric investigation plan for pazopanib (Votrient) (EMEA-000601-PIP01-09-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

An agency of the European Union

European Medicines Agency decision

P/0061/2016

of 18 March 2016

on the acceptance of a modification of an agreed paediatric investigation plan for pazopanib (Votrient) (EMEA-000601-PIP01-09-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/4/2011 issued on 3 January 2011, the decision P/0191/2012 issued on 24 August 2012 and the decision P/0132/2014 issued on 10 June 2014,

Having regard to the application submitted by Novartis Europharm Limited on 6 November 2015 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 January 2016, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for pazopanib (Votrient), film-coated tablet, age-appropriate oral formulation, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Novartis Europharm Limited, Frimley Business Park, GU16 7SR – Camberley, United Kingdom.

Done at London, 18 March 2016

For the European Medicines Agency
Zaïde Frias
Head of Division
Human Medicines Research and Development Support
(Signature on file)

EMA/PDCO/746683/2015 corr
London, 29 January 2016

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000601-PIP01-09-M03

Scope of the application

Active substance(s):

Pazopanib

Invented name:

Votrient

Condition(s):

Treatment of rhabdomyosarcoma

Treatment of non-rhabdomyosarcoma soft tissue sarcoma

Treatment of Ewing sarcoma family of tumours

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Age-appropriate oral formulation

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Novartis Europharm Limited

Information about the authorised medicinal product:

See Annex II

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Limited submitted to the European Medicines Agency on 6 November 2015 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/4/2011 issued on 3 January 2011, the decision P/0191/2012 issued on 24 August 2012 and the decision P/0132/2014 issued on 10 June 2014.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 30 November 2015.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Conditions:

Treatment of rhabdomyosarcoma

Treatment of non-rhabdomyosarcoma soft tissue sarcoma

Treatment of Ewing sarcoma family of tumours

The waiver applies to:

- the paediatric population from birth to less than 2 year of age;
- for film-coated tablet and age-appropriate oral formulation, oral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric Investigation Plan

2.1. Conditions:

Treatment of rhabdomyosarcoma

Treatment of non-rhabdomyosarcoma soft tissue sarcoma

Treatment of Ewing sarcoma family of tumours

2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients with rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma or Ewing sarcoma family of tumours.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

- Film-coated tablet for oral use.
- Age-appropriate oral formulation for oral use.

2.1.4. Measures

Area	Number of studies	Description
Quality-related studies	1	Study 1: Development of an age-appropriate oral formulation
Non-clinical studies	2	Study 2 (G10052): Oral toxicity study in juvenile rats Study 3 (I10194): Oral toxicokinetic study in juvenile rats
Clinical studies	3	Study 4 (ADVL0815): Single-agent, non-controlled, dose-escalation, open-label, multicentre study to evaluate pharmacokinetics, pharmacodynamics and toxicity of pazopanib in children from 2 years to less than 18 years of age (and young adults) with refractory solid tumours. Study 5 (VEG116731/ADVL1322): Single-agent, non-controlled, open-label, multi-centre, stratified study to evaluate pharmacokinetics, pharmacodynamics, toxicity, safety and activity of pazopanib in children from 2 years to less than 18 years of age with a recurrent and / or refractory soft tissue sarcoma. Study 6: Open-label, randomised, multicentre, active-controlled study to evaluate toxicity, safety and efficacy of pazopanib in paediatric patients with a relapsed metastatic rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma or Ewing sarcoma family of tumours.

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By September 2021
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of renal cell carcinoma:

Authorised indication(s):

- Votrient is indicated for the first line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.

2. Treatment of soft tissue sarcoma

Authorised indication(s):

- Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

Authorised pharmaceutical form(s):

Film-coated tablet

Authorised route(s) of administration:

Oral use